The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease

dc.authorid0000-0002-7982-9262en_US
dc.authorid0000-0002-7982-9262en_US
dc.authorid0000-0003-3358-7330en_US
dc.authorid0000-0002-9290-6285en_US
dc.authorid0000-0002-7526-7151en_US
dc.authorid0000-0001-8551-6900en_US
dc.authorid0000-0000-2644-3503en_US
dc.authorid0000-0002-0936-2476en_US
dc.contributor.authorKırık, Ali
dc.contributor.authorDoğru, Teoman
dc.contributor.authorKeyik, Bahar Yanik
dc.contributor.authorŞen, Hacer
dc.contributor.authorEroğlu, Mustafa
dc.contributor.authorBaykan, Özgür
dc.contributor.authorBozyel, Emel Aslan
dc.contributor.authorErgene, Ayşe
dc.contributor.authorSelçuk, Eda
dc.contributor.authorTaşçı, İlker
dc.contributor.authorSönmez, Yusuf Alper
dc.date.accessioned2024-06-04T10:52:44Z
dc.date.available2024-06-04T10:52:44Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKırık, Ali (Balikesir Author)en_US
dc.description.abstractOBJECTIVE: Mitochondrial open reading frame of the 12s ribosomal RNA type-c (MOTS-c) is a novel identified mitochondrial signal transmission peptide that plays an important role in glucose, amino acid and lipid metabolism. In this study, we aimed to investigate the relationship of circulating MOTS-c level with noninvasive scores of fibrosis and the components of metabolic syndrome (MetS) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). PATIENTS AND METHODS: This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group. The MOTS-c level was measured by the ELISA method. Non-alcoholic fatty liver disease fibrosis score (NFS) and fibrosis 4 (FIB-4) were used to determine the level of liver fibrosis. Statistical analyses were performed using Statistical Package for Social Science 15.0 package program. RESULTS: One hundred fifty patients (male, n=57) with MAFLD [median age 41.0 (14) years] and 84 healthy controls (male, n=34) [median age 36.0 (22) years] were included in this study. Patients with MAFLD had significantly lower MOTS-c levels than the healthy controls (p=0.009). The MOTS-c level was significantly lower in subjects with MetS (n=48) compared to those without MetS (n=186) (p=0.01). In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS. CONCLUSIONS: Individuals diagnosed with MetS and MAFLD tend to have lower levels of MOTS-c. Additionally, these lower levels are inversely correlated with both the components of MetS and noninvasive fibrosis scores. MAFLD negatively correlated to the MetS components and noninvasive scores of fibrosis.en_US
dc.identifier.doi10.26355/eurrev_202309_33567
dc.identifier.endpage8080en_US
dc.identifier.issn1128-3602
dc.identifier.issue17en_US
dc.identifier.scopus2-s2.0-85172228832
dc.identifier.scopusqualityQ2
dc.identifier.startpage8074en_US
dc.identifier.urihttps://doi.org/10.26355/eurrev_202309_33567
dc.identifier.urihttps://hdl.handle.net/20.500.12462/14787
dc.identifier.volume27en_US
dc.identifier.wosWOS:001089946700021
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectLiver Fibrosisen_US
dc.subjectMAFLDen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectMOTS-cen_US
dc.titleThe relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
ali-kırık.pdf
Boyut:
393.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: